Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 5/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
| ▸ | BMP1 | P13497 | 2/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534663 | 0.92 | GNPAT (0.54) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL14005763 | 0.91 | BMP1 (0.45) | BACE1BACE2CASP3CASP1CASP7 | |
| SCHEMBL22310788 | 0.91 | GNPAT (0.47) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL29576249 | 0.87 | GNPAT (0.44) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL29487532 | 0.87 | GNPAT (0.44) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL7157952 | 0.87 | GNPAT (0.44) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL31634368 | 0.87 | KDM4E (0.51) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL4100803 | 0.86 | CASP1 (0.50) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL13194679 | 0.86 | CASP1 (0.50) | GNPATBACE1BACE2CASP3CASP1 | |
| SCHEMBL29310042 | 0.86 | CASP1 (0.50) | GNPATBACE1BACE2CASP3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552168-B1 | Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis | MERCK FROSST CANADA & CO. (CA) | 2003-04-22 | — | — | US | claimed |
| US-6552168-B1 | Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis | MERCK FROSST CANADA & CO. (CA) | 2003-04-22 | — | — | US | disclosed |